BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23599147)

  • 41. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
    Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
    Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
    Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
    Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of Sox10 labeling in metastatic breast carcinomas.
    Nelson ER; Sharma R; Argani P; Cimino-Mathews A
    Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH.
    Hemmings C; Broomfield A; Bean E; Whitehead M; Yip D
    Pathology; 2009; 41(4):356-60. PubMed ID: 19404848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases.
    Weissferdt A; Kalhor N; Rodriguez Canales J; Fujimoto J; Wistuba II; Moran CA
    Hum Pathol; 2017 Jan; 59():1-9. PubMed ID: 27569293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.
    Zhang L; Shimizu D; Killeen JL; Honda SA; Lu D; Stanoyevitch A; Lin F; Wang B; Monuki ES; Carbone M
    Hum Pathol; 2016 Jul; 53():159-67. PubMed ID: 26980026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NKX3.1 as a marker of prostatic origin in metastatic tumors.
    Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
    Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.
    Brevet M; Arcila M; Ladanyi M
    J Mol Diagn; 2010 Mar; 12(2):169-76. PubMed ID: 20093391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.
    Angulo B; Conde E; Suárez-Gauthier A; Plaza C; Martínez R; Redondo P; Izquierdo E; Rubio-Viqueira B; Paz-Ares L; Hidalgo M; López-Ríos F
    PLoS One; 2012; 7(8):e43842. PubMed ID: 22952784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CDX-2 Expression in Primary Lung Adenocarcinoma.
    Cowan ML; Li QK; Illei PB
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
    Hashimoto T; Osoegawa A; Takumi Y; Abe M; Kobayashi R; Miyawaki M; Takeuchi H; Okamoto T; Sugio K
    Lung Cancer; 2018 Oct; 124():241-247. PubMed ID: 30268468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
    Pinter F; Papay J; Almasi A; Sapi Z; Szabo E; Kanya M; Tamasi A; Jori B; Varkondi E; Moldvay J; Szondy K; Keri G; Dominici M; Conte P; Eckhardt S; Kopper L; Schwab R; Petak I
    J Mol Diagn; 2008 Mar; 10(2):160-8. PubMed ID: 18258923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinoma.
    Wang L; Zhang Z; Huang L; Li W; Lu Q; Wen M; Guo T; Fan J; Wang X; Zhang X; Fang J; Yan X; Ni Y; Li X
    Analyst; 2014 Jan; 139(2):455-63. PubMed ID: 24303521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.
    Jiang G; Fan C; Zhang X; Dong Q; Wang L; Liu Y; Dai S; Yang L; Zhang Y; Yu J; Wang E
    PLoS One; 2013; 8(3):e59183. PubMed ID: 23536868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
    Hasanovic A; Ang D; Moreira AL; Zakowski MF
    Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.